about
Differential expression of PRAMEL1, a cancer/testis antigen, during spermatogenesis in the mouseDerivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approachPRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPsThe tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promotersPreferentially Expressed Antigen of Melanoma Prevents Lung Cancer Metastasis.Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.Lung cancer: Biology and treatment options.Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.Molecular Insights on Post-chemotherapy Retinoblastoma by Microarray Gene Expression AnalysisThe preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.Cancer-testis genes as candidates for immunotherapy in breast cancer.Identification of Preferentially Expressed Antigen of Melanoma as a Potential Tumor Suppressor in Lung Adenocarcinoma.Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis.Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME.Promises and caveats of in silico biomarker discovery.Preferentially Expressed Antigen of Melanoma (PRAME) and Wilms' Tumor 1 (WT 1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival.PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo.
P2860
Q28587770-1ED18103-ABEE-49B6-A93F-E5779AEA673BQ28748329-CDA74E44-352E-4232-A13F-831A4C3315B8Q34608912-26ACD3D0-DF40-4A3E-B9FF-9384F6E92BE0Q35214905-61E8616B-24DC-4807-AADE-12E3F1B7D233Q36070956-CF9E722C-DBFD-4019-895C-5D7EE04415B3Q36075245-4028ADDA-5933-4E6D-8EDF-0087E07561D2Q36095397-8A752A21-27BB-4CF6-AE8D-D2BBB39C7257Q36328370-7428B5C0-C40D-417C-989A-8039BFF40EC8Q37082518-80894F29-AA71-43B0-997A-5959A55A7751Q37203063-6191929D-85B4-4815-B957-A92FB5ADDA1CQ37381700-186CDD77-BFCC-4BC9-B33C-2E405C3DD933Q37783631-9F0132D6-8D7B-4CBF-BF07-D30EC2EFE7EFQ38184648-CC3C552D-F208-4C69-A32A-B549BA9374FDQ38767458-0FB01FAF-505F-4E82-94B6-D723D9B9604FQ39456290-C7226237-2E74-4BFD-A9E4-0311EEBFF783Q39546197-3AF5925B-BFC6-48C2-B4E2-56D851D1266AQ42274601-801C1F4A-98C3-4F39-BDAD-3CC35333C173Q42424826-FCD2636B-BB23-4193-8238-621D32B4601AQ42767013-E3135CBE-8B49-48F2-9BBC-F12D4850856DQ43087749-A7995A0C-BED6-4C58-8EBF-AE5320319070
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
PRAME expression and clinical outcome of breast cancer
@en
type
label
PRAME expression and clinical outcome of breast cancer
@en
prefLabel
PRAME expression and clinical outcome of breast cancer
@en
P2093
P2860
P356
P1476
PRAME expression and clinical outcome of breast cancer
@en
P2093
A A M Hart
M T Epping
O Krijgsman
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604494
P407
P577
2008-07-22T00:00:00Z
P5875
P6179
1036721913